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Background: Triflusal is a drug that inhibits platelet aggregation. In this study we investigated the dose-exposure-
response relationship of a triflusal formulation by population pharmacokinetic (PK) and pharmacodynamic (PD) modeling
of its main active metabolite, hydroxy-4-(trifluoromethyl) benzoic acid (HTB).
Methods: This study was a randomized, open-label, multiple-dose, two-period, two-treatment, comparative crossover
design. All volunteers received a single oral loading dose of 900 mg of triflusal on Day 1, followed by a dose of
600 mg/day from Day 2 to 9. Using data from 34 healthy volunteers, 476 HTB plasma concentration data points and 340
platelet aggregation data points were used to construct PK and PD models respectively using NONMEM (version 6.2). As
the PD endpoint was qualitative, we implemented binary analysis of ‘inhibition’ and ‘non-inhibition’ rather than using the
actual value of the test. The final PK-PD model was evaluated using a visual predictive check (VPC) and bootstrap.
Results: The time-concentration profile of HTB over the entire dosing period was described by a one-compartment
model with a first-order formation rate constant for HTB. Weight was selected as a covariate for clearance and volume of
triflusal, respectively. The structure and the population estimates for triflusal PK were as follows: oral clearance (CL/F) = 0.2 ·
(weight/71.65)0.845 L/h, oral volume of distribution (V/F) = 8.3 · (weight/71.65) L, and kf = 0.341 h
−1. A sigmoid relationship
between triflusal concentration and the probability of significant inhibition with shape factor was chosen as the final PD
model. No time delay between concentration and response was identified. The final structure between predicted
concentration ðCypred;ijÞ and the probability of inhibition of platelet aggregation (IPA) relationship was as follows: Probability
of IPA ¼ C19pred;ij=ð84:919μg=mLþ C19pred;ijÞ. Thus, we concluded this relationship is more like quantal concentration-response
relationship. The current dosing regimen was considered to be efficacious based on the EC50 estimate of 84.9 μg/mL
obtained in this study.
Conclusions: A PK and binary probability PD model of triflusal was successfully developed for Korean healthy volunteers.
The model may be used to further prediction inhibition of platelet aggregation by triflusal.
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Triflusal (2-acetoxy-4-(trifluoromethyl) benzoic acid),
which is chemically related to salicylate [1] but is not a de-
rivative of acetylsalicylic acid, is an antiplatelet drug [2,3]
that selectively inhibits arachidonic acid (AA) metabolism
in platelets by irreversibly inhibiting cyclooxygenase-1
(COX-1) and reduces thromboxane B2 (TXB2) pro-
duction [4,5]. 2-Hydroxy-4-(trifluoromethyl) benzoic acid
(HTB), the main active metabolite of triflusal, is formed
by deacetylation upon passage through the liver [5]. Tri-
flusal is less effective in inhibiting COX-1 and reducing
TXB2 than aspirin, but more effective than HTB [4]. HTB
increases the effects of triflusal on COX-1 inhibition com-
pared with salicylic acid, the main metabolite of aspirin,
which competes with the prodrug for the active site on
the cyclooxygenase enzyme [5,6].
Several previous reports have described the pharmaco-
kinetic (PK) characteristics of triflusal. After oral admi-
nistration, triflusal is absorbed rapidly within the small
intestine, showing an absolute bioavailability of 83–100%
[7]. The plasma half-life (T1/2) is 0.5 ± 0.1 h for triflusal
and 34.4 ± 0.1 h for HTB [4]. More than 60% of the par-
ent drug is eliminated by the kidney [7] and the values
for renal clearance for triflusal and HTB were found to
be 0.8 ± 0.2 L/h and 0.18 ± 0.04 L/h, respectively [5,8].
HTB reaches steady-state levels after 8–10 days of treat-
ment [5].
The aim of this study was to quantitatively determine
the dose-exposure-response relationship of triflusal in
healthy Korean male subjects using a population ana-
lysis. Additionally, we suggest a method of binary ana-
lysis that might be applied to platelet aggregation data to
identify pharmacodynamic (PD) markers.
Methods
Inclusion and exclusion criteria
Volunteers aged 20–55 years and within 20% of their
ideal body weight [IBW (kg) = height (cm) − 100) × 0.9]
were enrolled in the study. Those who were not suitable
on the basis of physical examinations and routine la-
boratory tests (blood hematology, biochemistry, pro-
thrombin time, bleeding time, urinalysis) were excluded.
Study design and ethical considerations
The analysis was performed using data from a randomized,
open-label, multiple-dose, two-period, two-treatment, com-
parative crossover study involving 38 healthy adult males.
The clinical trial was conducted at Kyungpook National
University Hospital Clinical Trial Center (KNUH CTC) to
determine the bioequivalence and non-inferiority of two
different triflusal formulations, as reported previously [4].
The study was conducted in accordance with the
guidelines of Good Clinical Practice and the Declaration
of Helsinki and its amendments at the KNUH CTC, andwas approved by the institutional review board at
KNUH. Written informed consent was obtained from all
volunteers before their participation.
Study drugs and dosage regimen
Triflusal capsule (Disgren capsule, 300 mg), as the re-
ference formulation, and triflusal EC capsule (Disgren
enteric-coated capsule, 300 mg), as the test formulation
were manufactured and provided by Myung-In Pharm.
Co., Ltd (Seoul, Republic of Korea). The subjects received
the test or reference formulation in multiple doses,
followed by a 13-day washout period and subsequent ad-
ministration of the alternative formulation. During each
period, each subject received a single 900 mg oral loading
dose on Day 1, followed by a 600 mg/day maintenance
dose (given as two 300 mg capsules once daily) from Day
2 to 9.
Blood sampling procedures
For measurement of the plasma concentration of HTB
(PK), whole blood samples were obtained at time 0 (pre-
dose), and 24, 48, 96, 144, 168, 192, 192.5, 193, 194, 196,
199, 202, and 216 h after the first dose (from Day 1 to
Day 10). For platelet aggregation measurements (PD),
sampling was performed at time 0 (pre-dose), and 24,
48, 96, 144, 168, 192, 196, 202, and 216 h post-dose. The
overall sampling schema is presented in Figure 1.
Blood (7 mL) for PK analysis was collected into tubes
containing sodium heparin, and blood (3 mL) for PD ana-
lysis was collected into tubes containing 0.109 mmol/L so-
dium citrate. An aliquot (1 mL) of each plasma sample
was placed in a microcentrifuge tube containing 0.1 mL
0.1 M HCl to prevent degradation of triflusal in the
plasma. The remaining samples were chilled promptly on
crushed ice to maintain the distribution ratio between tri-
flusal and HTB [9].
HTB plasma concentration measurements
Concentrations of HTB, rather than triflusal, were mea-
sured in this study because the level of triflusal is too
low to be detected after 4 h when administered orally,
as reported by Lee et al. [4,10]. Blood samples were
analyzed by high-performance liquid chromatography
coupled with tandem mass spectrometry (HPLC-MS/
MS) [7]. Quantification was performed by multiple reac-
tion monitoring (MRM) transitions. A C18 column was
used to separate the components of the samples by
chromatography. Linear calibration curves were analyzed
in the range of 1 to 300 μg/mL HTB (coefficient of cor-
relation, r = 0.999). The lower limit of quantification of
HTB was 1 μg/mL. The intra-day and inter-day % CVs
for HTB were each less than 15%. Figure 2 shows the
plasma concentrations of HTB with respect to time.
Figure 1 PK and PD study designs. Subjects (n = 34) eligible for this study were given a 900 mg loading dose on day 1, followed by a 600 mg/day
maintenance dose on days 2, 3, 5, 7, 8, and 9. For PK assessment, blood samples were obtained at time 0, 24, 48, 96, 144, 168, 192, 192.5, 193, 194, 196,
199, 202 and 216 h. For PD assessment, blood samples were obtained at time 0, 24, 48, 96, 144, 168, 192, 196, 202, and 216 h. PK, pharmacokinetic;
PD, pharmacodynamic; IPA, inhibition of platelet aggregation.
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The tubes containing sodium citrate were centrifuged
(1,000 rpm, 10 min) and 500 μL of platelet-rich plasma
(PRP) was collected as the supernatant. The PRP was
transferred to microcentrifuge tubes, which were capped
to prevent changes in pH upon exposure to air, and the
samples were kept on ice. To obtain 500 μL of platelet-
poor plasma (PPP), the remaining sample in the original
tubes was centrifuged again (3,000 rpm, 10 min) [11].
Platelet aggregation in PRP was assessed using a Chro-
nolog optical aggregometer (Model 490-4D; Chrono-log,
Havertown, PA, USA). Cuvettes were lined up along the
two rows of the aggregometer, filled with 250 μL of PRP
or PPP, and warmed for 5 min at 37°C [12]. To measure
the degree of platelet aggregation, 0.5 μL AA was added
to the cuvettes as an agonist, and light transmissionFigure 2 Raw data plot of time-concentration-response profile. (a) Pro
over time. (b) Observed concentration and platelet aggregation at the timaggregometry was observed for 5 min. The aggregometer
was calibrated with a cuvette containing PRP, equaling
0% light transmission, as the baseline and with a second
cuvette containing PPP, equaling 100% light transmis-
sion, as the reference [13]. Based on analyses of the
blank plasma samples, which were validated in three in-
dividuals, the intra-day and inter-day precisions were
calculated as (SD/mean) × 100 (%) and ranged from 2.1
to 6.8% and from 2.1 to 7.6%, respectively [4].
Dataset
In the current study, PK and PD data from 34 healthy
volunteers who received the reference drug were used
for population PK-PD analysis. In total, 476 HTB
plasma concentration data points and 340 platelet ag-
gregation (%) data points were included. The latentfiles of observed individual and median HTB plasma concentration
e of PD sampling.
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and weight, and levels of albumin, creatinine, serum as-
partate transaminase (AST), and alanine transaminase
(ALT). Creatinine clearance (CLCR), calculated using
the Cockcroft-Gault equation, was also included.
Population PK-PD model development
The population PK-PD analysis was conducted by non-
linear mixed effects modeling using NONMEM (ver. 6.2;
Icon Development Solution, Ellicott City, MD, USA).
The estimate and the between-subject variability for
PK-PD parameters were investigated. The first-order
conditional estimation (FOCE) method with interaction
option was used whenever applicable [14]. The between-
subject variability of each parameter of the basic model
was applied using the exponential model:
Pij ¼ θj  exp ηij
 
where Pij is the value of the j
th parameter in the ith in-
dividual, θj is the typical value of the j
th population par-
ameter, and ηij is a random variable for the i
th individual
in the jth parameter. It is assumed that ηij is normally
distributed, with a mean of zero and a variance of ω2,
and that ηij ≈N(0, ωij
2). The residual variability, consist-
ing of intra-individual variability, experimental errors,
process noise, and/or model mis-specifications, was
modeled using additive (εadd,ij), proportional (εpro,ij), and
combined error structures. The combined additive and
proportional error model on the following equation was
initially applied to explain the gaps between the ob-
served values and those predicted by individual PK
parameters:
Cij ¼ Cpred;ij  1 þ εpro;ij
  þ εadd;ij
where Cij is the j
th observed value in the ith individual,
and εpro,ij and εadd,ij are the residual intra-individual vari-
ability with a mean of zero and variances of σ2pro and
σ2add , respectively. A similar approach was made to the
PD observations. The standard errors, which give infor-
mation on the precision of the parameter estimates,
were explored using NONMEM’s “$COVARIANCE”
step.
Models were evaluated using diagnostic scatter plots,
goodness-of-fit plots, and the log likelihood ratio test
(LRT). The results for LRT were considered statistically
significant if the objective function value (OFV) de-
creased by 3.84 (p = 0.05); this was used as a cut-off cri-
terion for model improvement.
For PK, various absorption functions and distribu-
tional (1-compartment vs. multi-compartment) models
were compared. When linking PK-PD relationship, two
different models – binary probability and inhibition ofbuild-up – were tried sequentially to find the best de-
scription on the PD data. The binary probability model
uses a form of relationship similar to the Michaelis-
Menten equation, Cγpred;ij=ðEC50γ þ Cγpred;ijÞ to explain in-
stantaneous PK-PD relationship. In this equation, Cpred,ij
is the estimated concentration over time for individuals,
EC50 is the plasma concentration corresponding to the
half-maximal response, and γ is the shape factor. To im-
plement this approach, the PD data (% platelet aggrega-
tion) was transformed to a binary format based upon the
finding that the distribution of PD observation (the ma-
ximum platelet aggregation observed in each sample)
was clearly bimodal (Figure 2). The values above 74%
were regarded as no inhibition of platelet aggregation
(IPA), and thus as DV = 0, whereas values below 74 were
regarded as IPA (DV = 1), according to a guideline
presenting the normal ranges for the degree (%) of
aggregation in platelet-rich plasma [15]. To find a reli-
able initial estimate for this model, a logistic regression
procedure was performed in advance. For a binary out-
put variable, Y, we can model conditional probability
P(Y = 1 | X = x) as a function of x [16]. Let π(x) be a
linear function of x, π(x) = P(Y = 1 | X = x). The model
can be written as π(x) = exp(β0 + β1x) / exp(β0 + β1x) + 1.
Equivalently, by a logit transformation, the logistic re-
gression model has a linear relationship, logit(π(x)) = log
(π(x) / 1 − π(x)) = β0 + β1x, where β0 is the intercept coef-
ficient and β1 is the slope coefficient, for which the sign
is positive or negative if π(x) is a strictly increasing or
decreasing function of x, respectively [17]. Using the fre-
quency of DV = 1 at each time point, the intercept (β0)
and slope (β1) were estimated using SAS software (ver.
9.2; SAS Institute, Inc., Cary, NC, USA). The inhibition
of build-up model was tried to evaluate whether there is
a time-delay between concentration and response in the
form of continuous variable. The differential equation
for platelet aggregation at a certain HTB concentration
is as follows [18]:
dR=dt ¼ kin  1− Imax  CÞ= IC50 þ Cð Þ−kout  Rð½
where dR/dt is the rate of change of the measured re-
sponse (R) over time, kin is the turnover input rate for
production of the response, Imax is the fraction repre-
senting the maximal capacity by which the drug can in-
hibit platelet aggregation (0 ≤ Imax ≤ 1), C is the HTB
concentration, IC50 is the median inhibition concentra-
tion, and kout is the turnover output rate of the response.
Covariate analysis
The parameter-covariate relationship, which explains
why PK and PD vary among individuals, was explored
using variables in the dataset. In the exploratory analysis,
scatter plots of one covariate versus another were used
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ters versus covariates. The numerical procedure used
generalized additive modeling (GAM), as implemented
in the Xpose library (ver. 4.4.0, Department of Pharma-
ceutical Biosciences of Uppsala University, Uppsala,
Sweden) [19] of the ‘R’ software (ver. 2.15.3; R Founda-
tion for Statistical Computing, Vienna, Austria). In this
procedure, a response random variable, Y, is regressed
on the individual covariates (Xj) according to the general
equation:





where the s0 is an intercept, and s1(X1), · · ·, sp(Xp) are
smooth functions that are estimated in a nonparametric
fashion. In the equation, candidate covariates with the
greatest decrease in the Akaike information criterion
were selected as final covariates in the PK model when
there was a reduction of at least 3.84 compared with the
previous model, and the relationship between the ran-
dom variable, η, for each parameter and the candidate
covariates was improved. Otherwise, they were dropped
from the model.
Graphical analyses using goodness-of-fit plots –
including observed-versus-population-predicted, observed-
versus-individual-predicted, and residual diagnostics –
were also conducted to diagnose the degree of model
development.
Model evaluation
Bootstrap was recruited to check the robustness of the
PK-PD model and parameter estimates. The median
value and 95% confidence interval for each parameter
were obtained from 1,000 bootstrap dataset. For the PK
model, a visual predictive check (VPC) was implemented
to further evaluate the accuracy and predictive perfor-
mance. A total of 1,000 replicate simulation was per-
formed and the 50th (estimated population median), 5th,
and 95th percentiles of the created concentrations plotted
against time were compared with the overlaid observed
concentrations. In addition, predicted concentration-
response relationship is plotted with the predicted prob-
ability of each concentration data observed at the time of
PD sampling.
Sample size determination
We considered the sample size for having an 80% power
at a significance level of 0.05 for bioequivalence trials. It
was calculated under the condition of the equivalence
limit of 22.3%, the true mean difference of 10%, and the
standard deviation of 24.2%. The calculation was per-
formed by a formula suggested from Chow et al. [20].
Volunteers were randomly assigned to one of twosequences with simple randomization using SAS soft-
ware (ver. 9.2; SAS Institute, Inc., Cary, NC, USA).
Statistical analyses
The demographic data were presented using descriptive
statistical analysis performed with the standard SPSS
package (version 12.0 for Windows, SPSS, College Station,
TX, USA). The mean, standard deviation, and range were
obtained for each variable.
Results
Study population
Volunteers were recruited from August 2008 to September
2008. In total, thirty-eight volunteers were enrolled in this
study. Four subjects dropped out because of severe dental
pain, a medication administration error, a missing follow-
up urinalysis, or platelet aggregation 1% of baseline in the
second period. Data from the remaining 34 subjects were
analyzed to construct the PK and PD models. According
to the CONSORT flow diagram, Figure 3 shows the sub-
ject disposition. The age, height, and weight (means ± SD)
of the subjects were 24.1 ± 1.7 years, 176.1 ± 4.9 cm, and
70.8 ± 9.0 kg, respectively (Table 1).
Population PK modeling
The time-concentration profile of HTB over the entire
multiple-dosing period was best described by a one-
compartment model with first-order formation rate
constant of HTB. This model was implemented in the
PREDPP library subroutine “ADVAN2 TRANS2” in
NONMEM. Residual variability was best described by
the proportional error model, which explained the dif-
ference between the predicted and observed values for
individuals and resulted in a significant decrease in the
OFV. Weight was selected as the only covariate candi-
date after GAM analysis which explains existing know-
ledge about the PK of the drug. The effect of weight on
CL/F and V/F was explained best with following each
equation:
CL=F ¼ θ1  weight=71:65ð Þθ4
V=F ¼ θ2  weight=71:65ð Þ
where θ1 and θ2 were the estimated typical values of
CL and V with a median weight (71.65) and θ4 was the
estimated influential factor for weight. Weight produced
30.782 (equivalent to p < 0.001, 1 degree of freedom) de-
crease in the minimized OFV as well as the change in
the random BSV for CL/F from 18.5% to 14.9% and for
V/F from 15.6% to 9.5% (as % CV). Because only one
demographic variable (weight) was selected as a mea-
ningful covariate, the process of backward covariate ex-
clusion was omitted.
Figure 3 CONSORT flow diagram of subject disposition.
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presented in Figure 4. Final estimates from the PK
model, explaining the mean value and the between-
subject variability, are listed in Table 2. The minimum
concentration at steady state (Css,min) was estimated to
be 103.5 μg/mL using the values of final population PK
parameters; in addition, the estimated value of the accu-
mulation factor was 2.26.
Population PD modeling
The binary probability model was selected as the final
PK-PD structure. The results of the estimation from this
PD model were as follows: γ = 19 and EC50 = 84.9 μg/mL.
In addition to these parameter estimates, informationTable 1 Demographic information of the healthy
volunteers
Group Number of subjects (n = 34)
mean ± SD (Min – Max)
Age (years) 24.1 ± 1.7 (21 – 28)
Height (cm) 176.1 ± 4.9 (167.1 – 184.2)
Weight (kg) 70.8 ± 9.0 (53.3 – 89.7)such as the observed and predicted number of times that
non-aggregation occurred at each time point is shown in
Table 3. The between-subject variability was only applied
to EC50 and was well explained. The values estimated
from the PD model are summarized in Table 2.
Model evaluation
The bootstrap results showed acceptable robustness of
the model and are presented together with the final esti-
mates in Table 2. The VPC result (Figure 5) showed that
the prediction of the simulated data well-matched the
observed concentration-time profiles. This graph, repre-
senting a visual internal validation of the model, showed
that most of the observed data points were overlaid bet-
ween the 5th and 95th percentiles.
Discussion
The PK and PD characteristics of triflusal were investi-
gated using a non-linear mixed effects analysis. The ob-
jective of this study was to develop a population PK and
PD model of the triflusal formulation, an established un-
coated capsule, in healthy Korean male subjects. Plasma
concentrations of the active metabolite, HTB, and the
Figure 4 Goodness-of-fit plots of the final population pharmacokinetic model. (a) OBS versus PRED; (b) OBS versus IPRED; (c) |IWRES| versus
IPRED; (d) CWRES versus time-after the last dose. Circle: observation; solid black line: line of identity; gray line: loess regression line. OBS,
observation; PRED, population prediction; IPRED, individual prediction; |IWRES|, absolute individual weighted residuals; CWRED, conditional
weighted residuals.
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to demonstrate the PK and PD properties. Reasonable
estimates for parameters of the PK model were obtained,
reflecting the potential for accurately predicting the
information sought. The plots of the observed con-
centrations versus population-predicted or individual-
predicted concentrations showed that the PK model was
well structured, and the plot of time versus conditional
weighted residuals suggested that the errors had homo-
geneous variances.Our final HTB PK structure includes first-order for-
mation and 1-compartment disposition. This is plausible
judging from the immediate increase in HTB concentra-
tion on the day of full-PK study after dosing time and
the rate of concentration increase which is the fastest at
immediate post-dose and decreases thereafter (Figure 2).
This finding is consistent to the model used by Valle
et al. [3]. On the contrary, Yun et al. [21] suggested a
2-compartment model for HTB disposition. But we con-
sidered this model would behavior like a 1-compartment
Table 2 Final estimates of population PK and PD parameters
Parameter Description (units) Estimates from final model Bootstrap results Shrinkage
(%)Estimate % RSEa Median (95% CI)
Fixed effect
Pharmacokinetic
CL/F = θ1 * (weight/71.65)θ4
θ1 TV of CL/F (L/h) for subject whose
weight = 71.65 kg
0.200 2.7 0.1998 (0.1995 – 0.2002)
θ4 Exponent of weight proportional to CL/F 0.845 17.4 0.840 (0.830 – 0.850)
Vd/F = θ2 * (weight/71.65)
θ2 TV of Vd (L) for subject whose
weight = 71.65 kg
8.300 2.7 8.281 (8.267 – 8.295)
kf = θ3 TV of kf (h
−1) 0.341 15.1 0.345 (0.341 – 0.348)
Pharmacodynamic
θ5 TV of EC50 (μg/mL) 84.9 4.0 85.19 (84.98 – 85.40)
θ6 TV of γ 19.2 22.4 20.70 (20.32 – 21.08)
BSV (%CV)
Pharmacokinetic
ω12 BSV for CL/F 14.9 21.0 14.4 (14.3 – 14.5) 0.6
ω22 BSV for Vd 9.5 57.8 8.6 (8.4 – 8.8) 40.2
ω32 BSV for kf 88.0 26.5 73.5 (72.8 – 74.1) 10.5
Pharmacodynamic
ω42 BSV for EC50 21.8 28.4 21.4 (21.2 – 21.5) 8.3
ω52 BSV for γ 0 (Fixed) NE - -
Residual error (σ2)b
Proportional error 0.098 6.5 0.0977 (0.0973 – 0.0981) 11.5
% RSE, % relative standard error; CI, confidence interval; CL/F, oral clearance; TV, typical value at population level; Vd/F, oral volume of distribution; kf, first-order
formation rate constant; EC50, HTB concentration at which the probability of IPA is 50%; γ, shape factor; BSV, between-subject variability; % CV, % coefficient of
variation; NE, not estimated.
a% RSE is calculated from ω2.
bAdditive residual error was not selected.







0 h 34 1 (3%) 0 (0%)
24 h 34 2 (6%) 2 (6%)
48 h 34 11 (32%) 11 (32%)
96 h 34 29 (85%) 25 (74%)
144 h 34 25 (74%) 28 (82%)
168 h 34 27 (79%) 30 (88%)
192 h 34 30 (88%) 30 (88%)
196 h 34 34 (100%) 34 (100%)
202 h 34 34 (100%) 34 (100%)
216 h 34 28 (82%) 30 (88%)
IPA, inhibition of platelet aggregation.
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compartments were much (approximately 60 times) lar-
ger than the elimination rate constant and the equili-
brium between compartments will be obtained within
1 h after dose. Judging from the time of maximum
plasma concentration attainment (postdose 4–5 h), this
distributional characteristic might be superimposed by
the absorption as well as the elimination.
Covariate model building was established by the rela-
tionship between the subjects’ body features and parame-
ters in the PK model. Weight accounted for approximately
19 % and 39 % of between-subject variability for CL/F and
V/F, respectively, judging from the decrease of ω2 for cor-
responding parameters. Particularly, V/F was directly pro-
portional to weight (exponent = 1) and the fact suggested
that weight may be used as a scaling factor for triflusal
dose. However, definite conclusions could not be made
for following reason; 1) this study did not consider the
PK of triflusal; thus, weight might be influential to the
Figure 5 Results of model evaluation. (a) Visual predictive check result. The 5th and 95th percentiles (dashed gray line) and the median value
(solid black line) from the simulated data are plotted against the observed concentration data (circle) according to time. (b) Predicted HTB
concentration-probability of IPA curve; Circle: expected IPA for each HTB concentration measured at the time of PD observation; IPA, inhibition of
platelet aggregation.
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HTB (which was only explained with F in this study),
2) the clinical significance of this finding needs further
investigations together with its pharmacodynamics
variability, therapeutic index and clinical effectiveness.
In addition, even though HTB is mainly (>60%) excreted
in urine, CLCR was not selected as a meaningful covariate
for HTB CL/F. We consider that the effect of weight
superimposed that of CLCR. It was expected that studies
involving triflusal and HTB PK in patients with various
renal function will be essential to elucidate the exact
influence of renal function.
Based on the value of EC50 (=84.9 μg/mL) estimated in
this study, the current dosing regimen was considered to be
efficacious judging from the Css,min value (=103.5 μg/mL)
and the concentration-response relationship which
showed quantal characteristics (γ = 19). The saturated
value of Emax as 1 seemed reasonable, because there was
no significant model improvement when the parameter
was allowed to be estimated.
Another method, the binary probability model to con-
struct the PD model using transformed binary data, was
introduced to show characteristics of the PD data with-
out much information loss. This model resulted in suc-
cessful explanation of binary data characteristics by the
estimates, even though a turnover model was not con-
structed because of the modified binary data charac-
teristics. To date, this is the first report evaluating
quantitative PD data transformed into qualitative binarydata possessing one of two values. We recommend this
new approach of using probability to estimate parame-
ters that show predictive ability for the presence of
platelet aggregation. This model also provided a specific
method for potential use with binary data in the case of
high intra-individual variability for PD.
This study has some limitations. First, only HTB con-
centrations were used in our population PK and PD model
without measurement of the parent drug. Although tri-
flusal is a prodrug which has no pharmacologic effect, if a
study involving the concentration measurement of both
triflusal and HTB is conducted, a better description for
the HTB formation will be obtained. This approach may
enable the identification of influential factors for HTB for-
mation process including first-pass metabolism and he-
patic clearance of triflusal. Second, despite the possible
loss of information from the data transformation, a PD
model using probability (binary data model) was devel-
oped to evaluate the extreme values in our PD data, as
seen in the scatter diagram. To overcome this problem,
more accurate and precise quantitative analytic method to
measure the degree of platelet aggregation should be
required.
Using the VPC, which is one method of model evalua-
tion, prediction is possible when given not only different
dosage- and time-concentrations but also the probability
of IPA. Accordingly, optimal dosage regimens could be
determined by model-fitted parameter estimates without
additional clinical trials. The model may be clinically
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ducted in healthy volunteers, rather than in patients.
Thus, it is also necessary to construct a model estimating
reasonable parameters from patients in a more realistic
setting.
Conclusions
A PK and binary probability PD model of triflusal was
successfully developed for Korean healthy volunteers.
The model may be used to further predict inhibition of
platelet aggregation by triflusal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SMP constructed and developed the PK and PD models and drafted the
manuscript. JL, SJS, JGP, MRG, MSL, HWL, DHY, and YRY helped prepare
datasets, develop the PK and PD models, and interpret the results of the
estimated parameters. KIK and SH designed and supervised the clinical study,
developed the PK and PD models, and edited the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This research was supported by grants from the National Project for
Personalized Genomic Medicine, Ministry of Health & Welfare, Republic of
Korea (A111218-PG02); the Bio & Medical Technology Development Program
of the National Research Foundation (NRF) funded by the Ministry of
Science, ICT & Future Planning, Republic of Korea (NRF-2013M3A9B6046416);
the Pfizer Modeling & Simulation Education Center in Korea (PMECK); and
the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of
Korea (A070001).
Author details
1Clinical Trial Center, Kyungpook National University Hospital, Daegu, South
Korea. 2Department of Biomedical Science, Kyungpook National University
Graduate School, Daegu, South Korea. 3BK21 Plus KNU Bio-Medical Convergence
Program for Creative Talent, Kyungpook National University Graduate School, 680
Gukchaebosang-ro, Jung-gu, Daegu 700-842, South Korea. 4College of Pharmacy,
Yeungnam University, Daegu, South Korea. 5Department of Internal Medicine,
Division of Cardiology, Kyungpook National University School of Medicine, Daegu,
South Korea. 6College of Pharmacy, Chungnam National University, Daejeon, South
Korea. 7Department of Pharmacology, College of Medicine, The Catholic University
of Korea, Seoul, South Korea. 8PIPET (Pharmacometrics Institute for Practical
Education and Training), Seoul, South Korea.
Received: 21 May 2014 Accepted: 12 December 2014
Published: 23 December 2014
References
1. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jiménez MD, Lago A, Melo
T: Comparison of triflusal and aspirin for prevention of vascular events in
patients after cerebral infarction: the TACIP Study: a randomized,
double-blind, multicenter trial. Stroke 2003, 34:840–848.
2. McNeely W, Goa KL: Triflusal. Drugs 1998, 7:823–833.
3. Valle M, Barbanoj MJ, Donner A, Izquierdo I, Herranz U, Klein N, Eichler HG,
Müller M, Brunner M: Access of HTB, main metabolite of triflusal, to
cerebrospinal fluid in healthy volunteers. Eur J Clin Pharmacol 2005,
61:103–111.
4. Lee HW, Lim MS, Seong SJ, Lee J, Park J, Seo JJ, Yun HY, Baek IH, Kwon KI, Yoon
YR: A phase I study to characterize the multiple-dose pharmacokinetics,
pharmacodynamics and safety of new enteric-coated triflusal formulations
in healthy male volunteers. Expert Opin Drug Metab Toxicol 2011, 7:1471–1479.
5. Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G,
Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of
its action, use, safety and effectiveness. Hellenic J Cardiol 2009,
50:199–207.6. Rao GH, Reddy KR, White JG: Effect of acetaminophen and salicylate on
aspirin-induced inhibition of human platelet cyclo-oxygenase.
Prostaglandins Leukot Med 1982, 9:109–115.
7. Murdoch D, Plosker GL: Triflusal: a review of its use in cerebral infarction
and myocardial infarction, and as thromboprophylaxis in atrial
fibrillation. Drugs 2006, 66:671–692.
8. Gonzalez-Correa JA, De La Cruz JP: Triflusal: an antiplatelet drug with a
neuroprotective effect? Cardiovasc Drug Rev 2006, 24:11–24.
9. Cho HY, Jeong TJ, Lee YB: Simultaneous determination of triflusal and its
major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and
human plasma by high-performance liquid chromatography. J Chromatogr B
Analyt Technol Biomed Life Sci 2003, 798:257–264.
10. Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jane F: Pharmacokinetics of
triflusal and its main metabolite HTB in healthy subjects following a
single oral dose. Eur J Drug Metab Pharmacokinet 1991, 16:269–273.
11. Dong HP, Wu HM, Chen SJ, Chen CY: The effect of butanolides from
Cinnamomum tenuifolium on platelet aggregation. Molecules 2013,
18:11836–11841.
12. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S:
Guidelines for the laboratory investigation of heritable disorders of
platelet function. Br J Haematol 2011, 155:30–44.
13. Zhou L, Schmaier AH: Platelet aggregation testing in platelet-rich plasma:
description of procedures with the aim to develop standards in the field.
Am J Clin Pathol 2005, 123:172–183.
14. Beal S, Sheiner L: NONMEM User’s Guide Part I. San Francisco: University of
California at San Francisco; 1992.
15. Chrono-log corporation: Instruction manual for the chrono-log model 490
optical aggregometers. Havertown, PA, USA; 2005:31.
16. Agresti A: Logistic Regression. In Categorical Data Analysis. 2nd edition.
New York: Wiley; 2002:166.
17. Casella G, Berger RL: Regression Models. In Statistical Inference. 2nd edition.
California: Wadsworth; 2001:592.
18. Gabrielsson J, Weiner D: Pharmacodynamic Concepts. In Pharmacokinetic
and Pharmacodynamic Data Analysis: Concepts and Applications. 4th edition.
Stockholm: Swedish Pharmaceutical Press; 2007:265.
19. Jonsson EN, Karlsson MO: Xpose–an S-PLUS based population pharmacokinetic/
pharmacodynamic model building aid for NONMEM. Comput Methods
Programs Biomed 1999, 58:51–64.
20. Chow SC, Wang H: On sample size calculation in bioequivalence trials.
J Pharmacokinet Pharmacodyn 2001, 28:155–169.
21. Yun HY, Kang W, Lee BY, Park S, Yoon YR, Yeul Ma J, Kwon KI: Semi-Mechanistic
Modelling and Simulation of Inhibition of Platelet Aggregation by
Antiplatelet Agents. Basic Clin Pharmacol Toxicol 2014. in press.
doi:10.1186/2050-6511-15-75
Cite this article as: Park et al.: Population pharmacokinetic and
pharmacodynamic modeling of transformed binary effect data of triflusal in
healthy Korean male volunteers: a randomized, open-label, multiple dose,
crossover study. BMC Pharmacology and Toxicology 2014 15:75.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
